Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Telik has announced that the European Patent Office has issued notices of allowance for two applications covering new compounds related to one of Telik's lead clinical candidates, Telintra.
Subscribe to our email newsletter
Telintra is currently in Phase II clinical trials for the treatment of myelodysplastic syndrome, a form of pre-leukemia, and for chemotherapy induced neutropenia, a common side effect of chemotherapy.
Telik expects these applications and patents to provide broad intellectual property protection to compounds related to Telintra. The patents will help to broaden and strengthen Telik’s intellectual property estate and may support additional clinical development candidates.